Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Lacy
Martha Q
MQ
Division of Hematology, Mayo Clinic, Rochester, MN 55905.
Rajkumar
S Vincent
SV
D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; C467566:pomalidomide